Iza-Bren Improves PFS vs Platinum Chemo in EGFR-Mutated NSCLC After Third-Generation TKI
Izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) vs platinum-based chemotherapy in patients with EGFR-mutated nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed on...
